Prevention, Diagnosis, and Treatment of Hypertensive Heart Disease

被引:32
|
作者
Georgiopoulou, Vasiliki V. [1 ]
Kalogeropoulos, Andreas P. [1 ]
Raggi, Paolo [1 ]
Butler, Javed [1 ]
机构
[1] Emory Univ, Div Cardiol, Atlanta, GA 30322 USA
关键词
Hypertensive heart disease; Prevention; Treatment; LEFT-VENTRICULAR HYPERTROPHY; END-POINT REDUCTION; TIME 3-DIMENSIONAL ECHOCARDIOGRAPHY; SYSTOLIC BLOOD-PRESSURE; MAGNETIC-RESONANCE; LOSARTAN INTERVENTION; MYOCARDIAL-INFARCTION; ATRIAL-FIBRILLATION; EJECTION FRACTION; SODIUM-INTAKE;
D O I
10.1016/j.ccl.2010.07.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hypertensive heart disease (HHD), a result of long-standing hypertension, is characterized by changes in the myocardial structure and function in the absence of other primary cardiovascular abnormalities. Although increased blood pressure is the initiating stimulus, neurohormonal factors, particularly the renin-angiotensin system, play a key role in remodeling of cardiac chamber geometry and walls. Optimal antihypertensive therapy in the setting of therapeutic lifestyle changes is crucial in the prevention and control of HHD. Regression of left ventricular hypertrophy (LVH) is achievable and associated with improved prognosis. However, prevention of myocardial remodeling before LVH establishes would further increase the benefits to cardiac function and prognosis. Antihypertensive agents exhibit variable effectiveness in inducing LVH regression. Currently, renin-angiotensin system blocking agents seem to be the most effective approach for LVH regression and reverse remodeling in these patients.
引用
收藏
页码:675 / +
页数:18
相关论文
共 50 条
  • [31] Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact
    MacLeod, Mairi
    Papi, Alberto
    Contoli, Marco
    Beghe, Bianca
    Celli, Bartolome R.
    Wedzicha, Jadwiga A.
    Fabbri, Leonardo M.
    RESPIROLOGY, 2021, 26 (06) : 532 - 551
  • [32] Hypertensive Heart Disease: A Narrative Review Series-Part 3: Vasculature, Biomarkers and the Matrix of Hypertensive Heart Disease
    Nemtsova, Valeriya
    Vischer, Annina S.
    Burkard, Thilo
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (02)
  • [33] Reversibility of left ventricular mechanical dysfunction in patients with hypertensive heart disease
    Cheng, Susan
    Shah, Amil M.
    Albisu, Juan Pablo
    Desai, Akshay S.
    Hilkert, Robert J.
    Izzo, Joseph
    Oparil, Suzanne
    Pitt, Bertram
    Solomon, Scott D.
    JOURNAL OF HYPERTENSION, 2014, 32 (12) : 2479 - 2487
  • [34] Acute rheumatic fever and rheumatic heart disease: updates in diagnosis and treatment
    Rwebembera, Joselyn
    Beaton, Andrea
    CURRENT OPINION IN PEDIATRICS, 2024, 36 (05) : 496 - 502
  • [35] Hypertensive Heart Disease and the Role of Aldosterone Antagonists
    Roongsritong, Chanwit
    Kumar, Ashwani
    Jenkins, Leigh Ann
    CURRENT HYPERTENSION REVIEWS, 2007, 3 (02) : 137 - 142
  • [36] Cardiotrophin-1 in hypertensive heart disease
    Gonzalez, Arantxa
    Lopez, Begona
    Ravassa, Susana
    Beaumont, Javier
    Zudaire, Amaia
    Gallego, Idoia
    Brugnolaro, Cristina
    Diez, Javier
    ENDOCRINE, 2012, 42 (01) : 9 - 17
  • [37] Fragmented QRS: A marker of hypertensive heart disease?
    Mani, Arya
    JOURNAL OF CLINICAL HYPERTENSION, 2017, 19 (09) : 866 - 867
  • [38] Atrophic Cardiomyocyte Signaling in Hypertensive Heart Disease
    Kamalov, German
    Zhao, Wenyuan
    Zhao, Tieqiang
    Sun, Yao
    Ahokas, Robert A.
    Marion, Tony N.
    Al Darazi, Fahed
    Gerling, Ivan C.
    Bhattacharya, Syamal K.
    Weber, Karl T.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2013, 62 (06) : 497 - 506
  • [39] Diagnosis and treatment of adults with congenital heart disease
    Henning, Robert J.
    FUTURE CARDIOLOGY, 2020, 16 (04) : 317 - 342
  • [40] Renal insufficiency is associated with admission diagnosis and length of stay in patients with hypertensive heart disease and atrial fibrillation
    Umam, Faris Jaisyi
    Akbar, Fadhian
    Soenarta, Arieska Ann
    Widyantoro, Bambang
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2019, 21 (0F) : F57 - F57